S'abonner

Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies - 05/09/19

Doi : 10.1016/j.jaci.2019.02.017 
Elena Blanco, PhD a, b, , Martín Pérez-Andrés, PhD a, b, , Sonia Arriba-Méndez, MD, PhD c, Cristina Serrano, MD d, Ignacio Criado, PhD a, b, Lucía Del Pino-Molina, PhD e, Susana Silva, MD, PhD f, Ignacio Madruga, MD g, Marina Bakardjieva, MSc h, Catarina Martins, PhD i, Ana Serra-Caetano, MSc f, Alfonso Romero, MD j, Teresa Contreras-Sanfeliciano, MD k, Carolien Bonroy, PhD l, Francisco Sala, MD m, Alejandro Martín, MD, PhD n, o, José María Bastida, MD, PhD n, o, Félix Lorente, MD, PhD c, Carlos Prieto, PhD p, Ignacio Dávila, MD, PhD q, Miguel Marcos, MD, PhD g, Tomas Kalina, MD, PhD h, Marcela Vlkova, PhD r, Zita Chovancova, MD, PhD r, Ana Isabel Cordeiro, MD s, Jan Philippé, MD, PhD l, Filomeen Haerynck, MD, PhD t, Eduardo López-Granados, MD, PhD e, Ana E. Sousa, PhD f, Mirjam van der Burg, PhD u, v, Jacques J.M. van Dongen, MD, PhD w, , Alberto Orfao, MD, PhD a, b, ,
on behalf of the

EuroFlow PID group

a Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain 
b Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), number CB16/12/00400, Instituto de Salud Carlos III, Madrid, Spain 
c Servicio de Pediatría, Hospital Universitario de Salamanca, Salamanca, Spain 
k Servicio de Bioquímica Clínica, Hospital Universitario de Salamanca, Salamanca, Spain 
d Servicio de Inmunología, Fundación Jiménez Díaz, Madrid, Spain 
e Clinical Immunology Department, University Hospital La Paz and Physiopathology of Lymphocytes in Immunodeficiencies Group, IdiPAZ Institute for Health Research, Madrid, Spain 
f Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal 
g Servicio de Medicina Interna, Hospital Universitario de Salamanca, Institute for Biomedical Research of Salamanca, Department of Medicine, University of Salamanca, Salamanca, Spain 
h CLIP, Department of Haematology/Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic 
i NOVA Medical School/Faculdade de Ciências Médicas Universidade Nova de Lisboa, Lisbon, Portugal 
j Centro de Salud Miguel Armijo, Salamanca, Spain 
l Department of Laboratory Medicine, University Hospital Ghent, Ghent, Belgium 
t Department of Respiratory Diseases and Department of Pediatrics and Genetics, University Hospital Ghent, Ghent, Belgium 
m Servicio de Hematología, Hospital de Navarra, Pamplona, Spain 
n Servicio de Hematología, Hospital Universitario de Salamanca, Institute for Biomedical Research of Salamanca, Salamanca, Spain 
o Biomedical Research Networking Centre Consortium of Oncology (CIBERONC) number CB/16/12/00233, Instituto de salud Carlos III, Madrid, Spain 
p Bioinformatics service (NUCLEUS), University of Salamanca, Salamanca, Spain 
q Servicio de Alergia, Hospital Universitario de Salamanca, Institute for Biomedical Research of Salamanca, Biomedical and Diagnosis Science Department, University of Salamanca (USAL), Salamanca, Spain 
r Department of Clinical Immunology and Allergology, St Anne's University Hospital, and Faculty of Medicine, Masaryk University, Brno, Czech Republic 
s Hospital D. Estefânia, CHLC, Lisbon, Portugal 
u Department of Immunology, Erasmus MC, Rotterdam, The Netherlands 
v Department of Pediatrics, Laboratory for Immunology, Leiden University Medical Center, Leiden, The Netherlands 
w Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands 

Corresponding author: Alberto Orfao, MD, PhD, Department of Medicine, Cancer Research Center, University of Salamanca, Paseo de la Universidad de Coimbra s/n, 37007 Salamanca, Spain.Department of MedicineCancer Research CenterUniversity of SalamancaPaseo de la Universidad de Coimbra s/nSalamanca37007Spain

Abstract

Background

Predominantly antibody deficiencies (PADs) are the most prevalent primary immunodeficiencies, but their B-cell defects and underlying genetic alterations remain largely unknown.

Objective

We investigated patients with PADs for the distribution of 41 blood B-cell and plasma cell (PC) subsets, including subsets defined by expression of distinct immunoglobulin heavy chain subclasses.

Methods

Blood samples from 139 patients with PADs, 61 patients with common variable immunodeficiency (CVID), 68 patients with selective IgA deficiency (IgAdef), 10 patients with IgG subclass deficiency with IgA deficiency, and 223 age-matched control subjects were studied by using flow cytometry with EuroFlow immunoglobulin isotype staining. Patients were classified according to their B-cell and PC immune profile, and the obtained patient clusters were correlated with clinical manifestations of PADs.

Results

Decreased counts of blood PCs, memory B cells (MBCs), or both expressing distinct IgA and IgG subclasses were identified in all patients with PADs. In patients with IgAdef, B-cell defects were mainly restricted to surface membrane (sm)IgA+ PCs and MBCs, with 2 clear subgroups showing strongly decreased numbers of smIgA+ PCs with mild versus severe smIgA+ MBC defects and higher frequencies of nonrespiratory tract infections, autoimmunity, and affected family members. Patients with IgG subclass deficiency with IgA deficiency and those with CVID showed defects in both smIgA+ and smIgG+ MBCs and PCs. Reduced numbers of switched PCs were systematically found in patients with CVID (absent in 98%), with 6 different defective MBC (and clinical) profiles: (1) profound decrease in MBC numbers; (2) defective CD27+ MBCs with almost normal IgG3+ MBCs; (3) absence of switched MBCs; and (4) presence of both unswitched and switched MBCs without and; (5) with IgG2+ MBCs; and (6) with IgA1+ MBCs.

Conclusion

Distinct PAD defective B-cell patterns were identified that are associated with unique clinical profiles.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Immunodeficiency, primary antibody deficiency, selective IgA deficiency, common variable immunodeficiency, immunophenotyping, immunoglobulins, immunoglobulin subclasses, memory B cells, plasma cells, flow cytometry, diagnosis, classification

Abbreviations used : CVID, ESID, GC, HD, IgAdef, IgG/Adef, IgH, IUIS, LLN, MBC, NPV, PAD, PC, PPV, sm


Plan


 E.B. was supported by a grant from the Junta de Castilla y León (Fondo Social Europeo, ORDEN EDU/346/2013, Valladolid, Spain). This work was supported by the CB16/12/00400 and CB/16/12/00233 grants (CIBERONC, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid, Spain, and FONDOS FEDER), the FIS PI12/00905-FEDER grant (Fondo de Investigación Sanitaria of Instituto de Salud Carlos III, Madrid, Spain) and a grant from Fundación Mutua Madrileña (Madrid, Spain). The coordination and innovation processes of this study were supported by the EuroFlow Consortium.
 Disclosure of potential conflict of interest: E. Blanco, M. Pérez-Andrés, T. Kalina, M. Vlkova, E. López-Granados, M. van der Burg, J. J. M. van Dongen, and A. Orfao each report being one of the inventors on the EuroFlow-owned patent PCT/NL 2015/050762 (Diagnosis of primary immunodeficiencies), which is licensed to Cytognos, a company that pays royalties to the EuroFlow Consortium. J. J. M. van Dongen and A. Orfao report an Educational Services Agreement from BD Biosciences. The rest of the authors declare that they have no relevant conflicts of interest.


© 2019  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 144 - N° 3

P. 809-824 - septembre 2019 Retour au numéro
Article précédent Article précédent
  • The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungs
  • Timothy N. Perkins, Elizabeth A. Oczypok, Regina E. Dutz, Mason L. Donnell, Michael M. Myerburg, Tim D. Oury
| Article suivant Article suivant
  • Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome
  • Lucia Sereni, Maria Carmina Castiello, Dario Di Silvestre, Patrizia Della Valle, Chiara Brombin, Francesca Ferrua, Maria Pia Cicalese, Loris Pozzi, Maddalena Migliavacca, Maria Ester Bernardo, Claudio Pignata, Roula Farah, Lucia Dora Notarangelo, Nufar Marcus, Lorella Cattaneo, Marco Spinelli, Stefania Giannelli, Marita Bosticardo, Koen van Rossem, Armando D'Angelo, Alessandro Aiuti, Pierluigi Mauri, Anna Villa

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.